Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 1.00 |
| ▸ | BRD2 | P25440 | 1/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.73 |
| ▸ | TSPO | P30536 | 1/20 | 0.73 |
| ▸ | EP300 | Q09472 | 1/20 | 0.73 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.73 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27361460 | 0.91 | BRD4 (0.84) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL29745734 | 0.91 | BRD4 (1.00) | BRD4 | |
| SCHEMBL15067826 | 0.91 | BRD4 (1.00) | BRD4 | |
| SCHEMBL15069568 | 0.90 | BRD4 (1.00) | BRD4 | |
| SCHEMBL29745692 | 0.89 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL15069312 | 0.89 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL27362155 | 0.89 | BRD4 (0.80) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL15069407 | 0.88 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL29745682 | 0.88 | BRD4 (1.00) | BRD4 | |
| SCHEMBL15069536 | 0.88 | BRD4 (1.00) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | claimed |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-08-05 | — | — | US | claimed |
| US-20180296566-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2018-10-18 | — | — | US | claimed |
| EP-2797918-B1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2017-11-29 | — | — | EP | claimed |
| US-9296741-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2016-03-29 | — | — | US | claimed |
| EP-2797918-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2014-11-05 | — | — | EP | claimed |
| CN-104136435-A | BROMODOMAIN INHIBITORS | ABBVIE INC | 2014-11-05 | — | — | CN | claimed |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-06-12 | — | — | US | claimed |
| WO-2013097601-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2013-07-04 | — | — | WO | claimed |
| WO-2013097052-A1 | BROMODOMAIN INHIBITORS | ABBOTT LABORATORIES (US) | 2013-07-04 | — | — | WO | claimed |
| WO-2024054955-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054956-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2022132049-A1 | TREATING CANCERS USING BET INHIBITORS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-06-23 | — | — | WO | disclosed |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-08-05 | — | — | US | disclosed |
| EP-2797918-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| CN-104136435-A | BROMODOMAIN INHIBITORS | ABBVIE INC | 2014-11-05 | — | — | CN | disclosed |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-06-12 | — | — | US | disclosed |
| WO-2013097601-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013097052-A1 | BROMODOMAIN INHIBITORS | ABBOTT LABORATORIES (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296566-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885BRD2 4/4885ADORA2B 832/4885 |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885BRD2 4/4885ADORA2B 832/4885 |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885BRD2 4/4885ADORA2B 832/4885 |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885BRD2 4/4885ADORA2B 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.